Data compiled by Redley Lamar · ChainSifter Intelligence
12Suppliers
11Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Vaxcyte, Inc. (PCVX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
26Total relationships
3Distinct source URLs
7High confidence
0.750Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Vaxcyte, Inc. Suppliers
Ticker
Name
Confidence
Evidence
SUTRO-BIOPHARMA
SUTRO-BIOPHARMA
92%
pursuant to which we purchase from Sutro Biopharma extract and custom reagents for use in manufacturing non-clinical and certain clinical supply of vaccine compositions utilizing the technology licen…
LONZA
LONZA
90%
Lonza will (i) construct and build out a dedicated suite (the "Suite") at Lonza's facilities in Visp, Switzerland to manufacture certain key components (including drug substance) for our proprietary …
Reciprocal relationship from TMO graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from PCVX graph: In September 2025, we also entered in…
In September 2025, we also entered into a master services agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (collectively, “Thermo Fisher”), pursuant to which Thermo…
GSK
GSK plc
72%
accines to prevent or treat serious infectious diseases. Key elements of our strategy include: • Advance our PCV candidates through clinical development and regulatory approval. Our PCV candidates, V…
GSK
GSK plc
72%
Reciprocal relationship from GSK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from GSK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from GSK grap…
Reciprocal relationship from MRK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from MRK grap…
accines to prevent or treat serious infectious diseases. Key elements of our strategy include: • Advance our PCV candidates through clinical development and regulatory approval. Our PCV candidates, V…
SNYNF
Sanofi
72%
cs. As part of our strategy to prepare for future commercialization of our PCV programs, Mr. Mullette will lead the continued development and execution of global commercialization, including pre-laun…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from PCVX graph: cs. As part of our strategy to prepare for future commercialization of our PCV programs, Mr. Mullette will lead the …
rrently expect or change their requirements regarding the data required to support a marketing application; • the costs of establishing additional manufacturing capacity to meet potential incremental…
Reciprocal relationship from STRO graph: Reciprocal relationship from PCVX graph: rrently expect or change their requirements regarding the data required to support a marketing application; • the cos…
Vaxcyte, Inc. Customers
Ticker
Name
Confidence
Evidence
GSK
GSK plc
72%
Reciprocal relationship from GSK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from GSK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from GSK grap…
GSK
GSK plc
72%
Our business and future success depends on our ability to successfully develop, obtain regulatory approval of, and then commercialize our PCV candidates, which include VAX-31, our 31-valent clinical …
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from SNYN…
SNYNF
Sanofi
72%
cs. As part of our strategy to prepare for future commercialization of our PCV programs, Mr. Mullette will lead the continued development and execution of global commercialization, including pre-laun…
Reciprocal relationship from STRO graph: Reciprocal relationship from PCVX graph: rrently expect or change their requirements regarding the data required to support a marketing application; • the cos…
rrently expect or change their requirements regarding the data required to support a marketing application; • the costs of establishing additional manufacturing capacity to meet potential incremental…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
ed to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcem…
GEORGIA-RESEARCH-FOUNDATION-INC
GEORGIA-RESEARCH-FOUNDATION-INC
62%
ed to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcem…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
expensed when the activity has been performed or when the goods have been received. We make significant judgments and estimates in determining accrued research and development liabilities as of each …
LONZA-LTD
LONZA-LTD
62%
regulatory authorities, which may require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application; • the costs of …
SUPPLY-AGREEMENTS-LONZA-LTD
SUPPLY-AGREEMENTS-LONZA-LTD
62%
g table presents the contractual maturities of our investments as of March 31, 2026 (in thousands): Fair Value Due in less than one year $ 1,476,335 Due in one to five years 1,004,017 Total $ 2,480,3…
Vaxcyte, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PCVX-DEBT
Debt stack $116.3M
90%
Market cache reports total debt of $116.3M.
PCVX-DEBT-11708
Warrants outstanding: 5463793
90%
xbrl warrant detail from xbrl 2026-03-31.
Vaxcyte, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Vaxcyte, Inc..
Vaxcyte, Inc. Ownership
Holder
Name
Confidence
Evidence
PCVX-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 338 tracked holders.
